plozasiran
AssetAlso ARO-APOC3, ADS-005, ADS-005 FREE ACID
Silences hepatic APOC3 expression through RNA interference to lower triglyceride levels.
- Stage
- Phase 3
- Modality
- Oligonucleotide
- Target
- Lipid and ceramide metabolism
- 2
- Indications
- 3
- Trials
- 1
- Developer
Indications
2Hypertriglyceridemia
Phase 3, Active not recruiting, NCT06822790, clinicaltrials.gov, 7 Oct 2026
Severe hypertriglyceridemia
Phase 3, Completed, NCT06347016, clinicaltrials.gov, 13 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials3
- Evidence for its targets3
- Competitors10
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.